Where does Abivax rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Abivax ranks #8,730 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Abivax hold?

Abivax holds 36 US utility patents granted between 2015 and 2025, spanning 12 technology areas.

What is Abivax's Innovation Score?

Abivax has an Innovation Score of 39.7 out of 100 (top 37% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Abivax focus on?

Abivax's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 29 patents, ranking #678 of 6,058 assignees active in that subclass. Grants appear in 12 CPC subclasses total.

Is Abivax's patent grant rate increasing or decreasing?

Abivax's recent grant velocity is +36% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Abivax's patents?

Abivax's patents average 15.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Abivax patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Abivax

USPTO PatentsView assignee record - 36 granted patents across 12 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Abivax ranks #8,730 of 49,997 tracked US assignees by granted-patent volume, with 36 patents across 12 technology areas.

#8,730
of 49,997 US assignees by volume: Top 37%
by Innovation Score (39.7/100): 15.7
avg claims per patent: +36%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R8730 · Foreign Corporation #8,730 · 36 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-UP · BOOK-FULL

GRANTS-SMALL 36 grants
UPPER-Q #8,730/49,997
PHOTO-FINISH 22 Evolution
CPC-FOCUS A61P · 12 areas
INNOV-THIN 39.7/100
CLAIMS-RICH 15.7 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-UP +36% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: 22 Evolution LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Abivax’s 39.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 12.5 pts (31%) Velocity 5.6 pts (14%) Breadth 12.2 pts (31%) Claim depth 9.4 pts (24%)

Qualcomm Incorporated · highest

85
Abivax · this assignee

40
Exactech · near

40
Schleifring · near

40
Zealand Pharma A/S · near

40
OIL States Energy… · near

40
3D Lighting… · lowest

7

What this shows Abivax's Innovation Score is 39.7/100 (top 37% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Abivax?

Each dot is one of Abivax’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Abivax’s own 15.7 claims/patent is ABOVE the 12.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Abivax vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Abivax's grants concentrate

Abivax is a focused PatentsView assignee: 12 CPC subclasses with 80.6% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2020 (6 grants) versus a trough of 2 in 2024. By volume, Abivax sits between iTool Equipment Holding LLC and ANI Technologies Private Limited.

Abivax's three-year grant acceleration

Abivax shows 10 grants in 2022–2024 against only 12 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

itool Equipment H…

37
22 Evolution

36
3-D Matrix

36
5 11

36
Aces

36
Adlink Technology

36
AIR Cruisers

36
ANI Private

36
Abivax ◀

36

What this shows Abivax holds 36 patents at rank #8,730, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Abivax

By rank, the assignees closest to #8,730 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Abivax's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Abivax, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Abivax ranks #678 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (40 here).

Exactech, Inc. 40 Zealand Pharma A/S 40 Schleifring GmbH 40 OIL States Energy Services, L.L.C. 40

Abivax's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

40 Top 37% higher than 63% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Abivax patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	4	11.1%
2017	3	8.3%
2018	4	11.1%
2019	3	8.3%
2020	6	16.7%
2021	3	8.3%
2022	4	11.1%
2023	4	11.1%
2024	2	5.6%
2025partial year	3	8.3%

Which technologies does Abivax patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 29

C07D - Heterocyclic Compounds 26

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 24

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 7

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 7

C07C - Acyclic OR Carbocyclic Compounds 5

Y02A - Technologies FOR Adaptation TO Climate Change 4

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 3

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 3

C07K - Peptides 2

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 1

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 1

Top 12 of 12 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Abivax's patent record in context - here's where to go next.

Abivax's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 80.6% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #8,730 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Abivax against iTool Equipment Holding LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 39.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.